Relay Debt To Equity from 2010 to 2025

RLAY Stock  USD 4.54  0.06  1.34%   
Relay Therapeutics Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2025. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.064
Current Value
0.0672
Quarterly Volatility
0.04914044
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Relay Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relay Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 37.5 M, Interest Income of 37.5 M or Depreciation And Amortization of 4 M, as well as many indicators such as Price To Sales Ratio of 45.17, Dividend Yield of 0.0 or PTB Ratio of 1.0. Relay financial statements analysis is a perfect complement when working with Relay Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Relay Therapeutics Correlation against competitors.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Latest Relay Therapeutics' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Relay Therapeutics over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Relay Therapeutics' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relay Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.06 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Relay Debt To Equity Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation466.60
Mean Deviation0.03
Median(0)
Standard Deviation0.05
Sample Variance0
Range0.2087
R-Value0.46
Mean Square Error0
R-Squared0.21
Significance0.08
Slope0
Total Sum of Squares0.04

Relay Debt To Equity History

2025 0.0672
2024 0.064
2023 0.0711
2022 0.0608
2021 0.0255
2020 0.032
2019 -0.14

About Relay Therapeutics Financial Statements

Relay Therapeutics investors use historical fundamental indicators, such as Relay Therapeutics' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Relay Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.06  0.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.